SUBSCRIBE
SUBSCRIBE

GV20 Therapeutics

NEWS
Business
BioSpace Movers & Shakers: Evommune, Maravai, Aptose & More
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
June 30, 2022
 · 
5 min read
 · 
Alex Keown
IN THE PRESS
Genetown
GV20 Therapeutics to Present at the Jefferies Healthcare Conference Private Biotech Day
May 22, 2024
 · 
1 min read
Genetown
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target
April 24, 2024
 · 
2 min read
Business
GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembrolizumab)
April 18, 2024
 · 
2 min read
Genetown
GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024
April 8, 2024
 · 
3 min read
Genetown
GV20 Therapeutics to Present at the Needham 23rd Annual Virtual Healthcare Conference
April 2, 2024
 · 
1 min read
Business
GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery
March 12, 2024
 · 
1 min read
Genetown
GV20 Therapeutics Announces Oral Presentation on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024
March 5, 2024
 · 
1 min read
Business
GV20 Therapeutics Announces Appointment of Three Advisers
July 20, 2022
 · 
6 min read
Business
GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives
June 29, 2022
 · 
5 min read
JOBS